Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban

The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the existing thrombus, warfarin and novel anticoagulants have been used. However, there has been no clinical information regarding the difference of the effects of congealing the fib...

Full description

Bibliographic Details
Main Authors: Yosuke Miwa, Toshinori Minamishima, Toshiaki Sato, Konomi Sakata, Hideaki Yoshino, Kyoko Soejima
Format: Article
Language:English
Published: Wiley 2016-06-01
Series:Journal of Arrhythmia
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1880427616000314
Description
Summary:The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the existing thrombus, warfarin and novel anticoagulants have been used. However, there has been no clinical information regarding the difference of the effects of congealing the fibrinogenolysis system among these oral anticoagulants. Here, we report a case of persistent AF, in whom apixaban, factor Xa inhibitor resolved an LAA clot refractory to warfarin and direct thrombin inhibition. Factor Xa inhibitor, apixaban, could resolve the left appendage thrombosis refractory to warfarin and dabigatran.
ISSN:1880-4276